<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=213807269037206&amp;ev=PageView&amp;noscript=1">
Compliance In Focus
Posted by John Lehmann on Mon, Apr 16, 2012

Significant Risk/Non-Significant Risk Determination Whitepaper

IMARC WhitepaperDr. Harvey Arbit of Arbit Consulting has penned a whitepaper for IMARC Research titled, “Significant Risk/Non-Significant Risk Determination and IDE Applicability.”  Although the Medical Device Amendments were enacted on May 28, 1976, it still seems that after all these years there is confusion and misunderstanding regarding the process for determining if an investigational device is Significant Risk (SR) or Non-Significant Risk (NSR).

Using algorithms, decision trees, or other tools can make this decision process simpler. Dr. Arbit provides us with 6 algorithms to consider:

  1. Categorization:  It deals with the overall categorization of the investigational article.
  2. IDE Status: After determining that the article is a medical device there are additional questions to be addressed.
  3. Risk Assessment:  It is at this point the algorithm turns to the important question of SR or NSR.
  4. Protocol Consideration: The study itself needs to be considered when assessing risk.
  5. IVD Considerations (if applicable): If the device is an IVD there is another series of questions to be answered.
  6. MRI Considerations (if applicable): MRI is a category of medical devices that has its own complex algorithm, and requires a number of questions be addressed.

It is important to keep in mind that risk determination is a task shared by sponsors, sponsor-investigators, IRBs, and the FDA, with the ultimate goal being to identify the appropriate level of risk so that appropriate safeguards can be put into place to protect patients.

Please take time to read this informative whitepaper and share your comments with Dr. Arbit or with us!

Topics: Dr. Harvey Arbit, Signficant Risk, Non-Signficant Risk, IMARC Research Whitepaper


Posts by Topic: